CRANDELL KEITH (CIK 1219039) reported 15 SEC Form 4 insider transactions across 9 companies over the past 18 months (most recent 2026-07-06). Recent activity: Buy BOLD (16,000 shares), Sell BOLD (16,000 shares), Buy KARD (1.2M shares), Buy KARD (13.8M shares), Buy MASS (14,083 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Boundless Bio, Inc. (BOLD) | 10% Owner | Buy | 16,000 | $16,480 |
| 2026-07-06 | Boundless Bio, Inc. (BOLD) | 10% Owner | Sell | 16,000 | $39,840 |
| 2026-06-24 | Kardigan, Inc. (KARD) | Director | Buy | 1.2M | $20.0M |
| 2026-06-22 | Kardigan, Inc. (KARD) | 10% Owner | Buy | 13.8M | $0 |
| 2026-06-12 | 908 Devices Inc. (MASS) | Director | Buy | 14,083 | $0 |
| 2026-05-04 | Seaport Therapeutics, Inc. (SPTX) | 10% Owner | Buy | 2.5M | $0 |
| 2026-05-04 | Seaport Therapeutics, Inc. (SPTX) | 10% Owner | Buy | 2.7M | $0 |
| 2026-05-04 | Seaport Therapeutics, Inc. (SPTX) | 10% Owner | Buy | 1.1M | $19.8M |
| 2026-03-09 | Lyell Immunopharma, Inc. (LYEL) | Insider | Buy | 488,090 | $12.5M |
| 2026-02-09 | Twist Bioscience Corp (TWST) | Director | Buy | 5,095 | $0 |
| 2025-11-14 | Metsera, Inc. (MTSR) | Director | Sell | 18.5M | $0 |
| 2025-11-14 | Metsera, Inc. (MTSR) | Director | Sell | 8.3M | $0 |
| 2025-10-29 | Neumora Therapeutics, Inc. (NMRA) | Insider | Buy | 1.9M | $5.0M |
| 2025-08-01 | Prime Medicine, Inc. (PRME) | Insider | Buy | 3.0M | $10.0M |
| 2025-06-13 | 908 Devices Inc. (MASS) | Director | Buy | 11,364 | $0 |
Source: SEC Form 4 filings · as of 2026-07-06